000289178 001__ 289178
000289178 005__ 20250514131752.0
000289178 0247_ $$2doi$$a10.1002/cam4.7126
000289178 0247_ $$2pmid$$apmid:38545829
000289178 0247_ $$2altmetric$$aaltmetric:161462797
000289178 037__ $$aDKFZ-2024-00613
000289178 041__ $$aEnglish
000289178 082__ $$a610
000289178 1001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b0$$eFirst author$$udkfz
000289178 245__ $$aCritical survival periods in prostate cancer in Sweden explored by conditional survival analysis.
000289178 260__ $$aHoboken, NJ$$bWiley$$c2024
000289178 3367_ $$2DRIVER$$aarticle
000289178 3367_ $$2DataCite$$aOutput Types/Journal article
000289178 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1738139399_9464
000289178 3367_ $$2BibTeX$$aARTICLE
000289178 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289178 3367_ $$00$$2EndNote$$aJournal Article
000289178 500__ $$a#EA:Z999#
000289178 520__ $$aWe wanted to characterize conditional survival in prostate cancer (PC) in Sweden around and after 2005 when the vast increase in incidence due to the opportunistic testing for prostate specific antigen (PSA) culminated. We hypothesize that analyzing survival data during that time period may help interpret survival trends. We focus on stage-specific analysis using conditional survival in order to define the periods when deaths most commonly occurred.Data on PC patients were obtained from the Swedish cancer registry for analysis of 1-, 2.5- and 5-year relative survival and conditional relative survival between years 2004 and 2018. Tumor-node-metastatic stage classification at diagnosis was used to specify survival.Small improvements were observed in stage- and age-related relative survival duriring the study period. Applying conditional relative survival showed that survival in stage T3 up to 2.5 years was better than survival between years 2.5 and 5. Survival in stage T4 was approximately equal in the first and the subsequent 2.5-year period. For M1, the first 2.5 year survival period was worse than the subsequent one. The proportion of high risk and M1 disease in old patients (80+ years) remained very high and their survival improved only modestly.The data indicate that M1 metastases kill more patients in the first 2.5 years than between years 2.5 and 5 after diagnosis; T4 deaths are equal in the two periods, and in T3 mortality in the first 2.5-year period is lower than between years 2.5 and 5 after diagnosis. Conditional survival could be applied to explore critical survival periods even past 5 years after diagnoses and to monitor success in novel diagnostic and treatment practices. Improvement of survival in elderly patients may require clinical input.
000289178 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000289178 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289178 650_7 $$2Other$$aage
000289178 650_7 $$2Other$$aconditional relative survival
000289178 650_7 $$2Other$$aprognosis
000289178 650_7 $$2Other$$astage
000289178 650_7 $$2Other$$atreatment
000289178 7001_ $$00000-0001-7600-7143$$aZitricky, Frantisek$$b1
000289178 7001_ $$aSundquist, Kristina$$b2
000289178 7001_ $$aSundquist, Jan$$b3
000289178 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b4$$udkfz
000289178 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b5
000289178 7001_ $$aHemminki, Otto$$b6
000289178 773__ $$0PERI:(DE-600)2659751-2$$a10.1002/cam4.7126$$gVol. 13, no. 7, p. e7126$$n7$$pe7126$$tCancer medicine$$v13$$x2045-7634$$y2024
000289178 8564_ $$uhttps://inrepo02.dkfz.de/record/289178/files/Cancer%20Medicine%20-%202024%20-%20Hemminki%20-%20Critical%20survival%20periods%20in%20prostate%20cancer%20in%20Sweden%20explored%20by%20conditional%20survival.pdf
000289178 8564_ $$uhttps://inrepo02.dkfz.de/record/289178/files/Cancer%20Medicine%20-%202024%20-%20Hemminki%20-%20Critical%20survival%20periods%20in%20prostate%20cancer%20in%20Sweden%20explored%20by%20conditional%20survival.pdf?subformat=pdfa$$xpdfa
000289178 8767_ $$8W-2024-00027-b$$92024-05-28$$d2024-12-18$$eAPC$$jZahlung erfolgt
000289178 909CO $$ooai:inrepo02.dkfz.de:289178$$popenCost$$pOpenAPC$$pVDB
000289178 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000289178 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000289178 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000289178 9141_ $$y2024
000289178 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000289178 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000289178 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000289178 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
000289178 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER MED-US : 2022$$d2023-10-26
000289178 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000289178 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000289178 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000289178 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-04-16T15:13:13Z
000289178 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-04-16T15:13:13Z
000289178 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Double anonymous peer review$$d2021-04-16T15:13:13Z
000289178 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-04-16T15:13:13Z
000289178 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000289178 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000289178 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000289178 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000289178 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000289178 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000289178 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-26
000289178 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000289178 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-26
000289178 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-26
000289178 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-26
000289178 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-26
000289178 9201_ $$0I:(DE-He78)Z999-20160331$$kZ999$$lErimitus im DKFZ$$x0
000289178 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000289178 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000289178 9200_ $$0I:(DE-He78)Z999-20160331$$kZ999$$lErimitus im DKFZ$$x0
000289178 980__ $$ajournal
000289178 980__ $$aVDB
000289178 980__ $$aI:(DE-He78)Z999-20160331
000289178 980__ $$aI:(DE-He78)B062-20160331
000289178 980__ $$aI:(DE-He78)HD01-20160331
000289178 980__ $$aAPC
000289178 980__ $$aUNRESTRICTED
000289178 9801_ $$aAPC